Dimitrios Fatouros

Prof. Dimitrios Fatouros

Department of Pharmacy, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2018 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
CGChristos I. Gioumouxouzis
Christos I. Gioumouxouzis
ABApostolos Baklavaridis
Apostolos Baklavaridis
OKOrestis L Katsamenis
Orestis L Katsamenis
CMCatherine K. Markopoulou
Catherine K. Markopoulou
NBNikolaos Bouropoulos
Nikolaos Bouropoulos
DFDimitrios Fatouros
Dimitrios Fatouros

1 January 2016 in Drug Discovery Today
Verified
Journal Article
Closed access
Christina KaravasiliChristina Karavasili
Christina Karavasili
DFDimitrios Fatouros
Dimitrios Fatouros

1 February 2019 in Drug Discovery Today
Verified
Journal Article
Closed access
CGChristos I. Gioumouxouzis
Christos I. Gioumouxouzis
Christina KaravasiliChristina Karavasili
Christina Karavasili
DFDimitrios Fatouros
Dimitrios Fatouros

1 November 2019 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
Georgios EleftheriadisGeorgios Eleftheriadis
Georgios Eleftheriadis
CRChristos Ritzoulis
Christos Ritzoulis
NBNikolaos Bouropoulos
Nikolaos Bouropoulos
Dimitrios TzetzisDimitrios Tzetzis
Dimitrios Tzetzis
DADimitrios A. Andreadis
Dimitrios A. Andreadis
DFDimitrios Fatouros
Dimitrios Fatouros

1 September 2019 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
IXIakovos Xenikakis
Iakovos Xenikakis
MTManolis Tzimtzimis
Manolis Tzimtzimis
Konstantinos TsongasKonstantinos Tsongas
Konstantinos Tsongas
DADimitrios Andreadis
Dimitrios Andreadis
EDEuterpi Demiri
Euterpi Demiri
DFDimitrios Fatouros
Dimitrios Fatouros

9 January 2020 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Eleftherios AndriotisEleftherios Andriotis
Eleftherios Andriotis
Georgios EleftheriadisGeorgios Eleftheriadis
Georgios Eleftheriadis
Christina KaravasiliChristina Karavasili
Christina Karavasili
DFDimitrios Fatouros
Dimitrios Fatouros
Biodegradable 3D-printable inks based on pectin have been developed as a system for direct and indirect wound-dressing applications, suitable for 3D printing technologies. The 3D-printable inks formed free-standing transparent films upon drying, with the latter exhibiting fast disintegration upon contact with aqueous media. The antimicrobial and wound-healing activities of the inks have been successfully enhanced by the addition of particles, comprised of chitosan and cyclodextrin inclusion complexes with propolis extract. Response Surface Methodology (RSM) was applied for the optimization of the inks (extrusion-printing pressure, shrinkage minimization over-drying, increased water uptake and minimization of the disintegration of the dry patches upon contact with aqueous media). Particles comprised of chitosan and cyclodextrin/propolis extract inclusion complexes (CCP), bearing antimicrobial properties, were optimized and integrated with the produced inks. The bioprinted patches were assessed for their cytocompatibility, antimicrobial activity and in vitro wound-healing properties. These studies were complemented with ex vivo skin adhesion measurements, a relative surface hydrophobicity and opacity measurement, mechanical properties, visualization, and spectroscopic techniques. The in vitro wound-healing studies revealed that the 3D-bioprinted patches enhanced the in vitro wound-healing process, while the incorporation of CCP further enhanced wound-healing, as well as the antimicrobial activity of the patches.